bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Authors: Huang Xinqiang , Magnus Jill , Kaimal Vivek , Karmali Priya , Li Jian , Walls Marlena , Prudente Rene , Sung Eric , Sorourian Mehran , Lee Robin , Davis Scott , Yang Xia , Estrella Heather , Lee Edmund C. , Chau B. Nelson , Pavlicek Adam , Zabludoff Sonya
Published: April 2023

Inhibition of miR-17 family by miR-17 TuD had no effect on caspase 3/7 activity. Caspase 3/7 activity was represented as relative activity compared to NC TuD expression cells.
Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Authors: Huang Xinqiang , Magnus Jill , Kaimal Vivek , Karmali Priya , Li Jian , Walls Marlena , Prudente Rene , Sung Eric , Sorourian Mehran , Lee Robin , Davis Scott , Yang Xia , Estrella Heather , Lee Edmund C. , Chau B. Nelson , Pavlicek Adam , Zabludoff Sonya
Published: April 2023

Inhibition of miR-17, 20a, 20b, 93 and 106b activity by miR-17 TuD in HeLa cells as determined by luciferase reporter assays.
Supplementary Figure S2: Transduction efficiency by Ad/HER2-ECD in organs and peritoneally disseminated tumor from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Authors: Ishida Michihiro , Kagawa Shunsuke , Shimoyama Kyoko , Takehara Kiyoto , Noma Kazuhiro , Tanabe Shunsuke , Shirakawa Yasuhiro , Tazawa Hiroshi , Kobayashi Hisataka , Fujiwara Toshiyoshi
Published: April 2023

Immunohistochemistry showed the diffuse HER2 expression on the disseminated peritoneal tumor, but not normal organs, including the liver and the small intestine. Original magnification, ï‚'40
Supplementary data, Figure 2 from Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Authors: Wang Xianhui , Wong Jason , Sevinsky Christopher J. , Kokabee Leila , Khan Faiza , Sun Yan , Conklin Douglas S.
Published: April 2023

Ibrutinib inhibition of BTK-C is irreversible, surviving wash-out in culture.
Morphological changes induced immediately after Tra-IR700-mediated PIT from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Authors: Ishida Michihiro , Kagawa Shunsuke , Shimoyama Kyoko , Takehara Kiyoto , Noma Kazuhiro , Tanabe Shunsuke , Shirakawa Yasuhiro , Tazawa Hiroshi , Kobayashi Hisataka , Fujiwara Toshiyoshi
Published: April 2023

Morphological changes induced immediately after Tra-IR700-mediated PIT in HER2-ECD-transduced gastric cancer cells captured as a time-lapse movie. The cells, which were treated with the integration of Ad/HER2-ECD and Tra-IR700-mediated PIT, shrunk without proliferation. Tra-IR700-mediated PIT cells and control adenovirus (Ad/GFP)-infected cells survived without any phototoxic or virus-toxic effects.
Supplrmentary Figures S1-S4 and Tables S1-S5 from Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome
Authors: Raynal Noël J.-M. , Da Costa Elodie M. , Lee Justin T. , Gharibyan Vazganush , Ahmed Saira , Zhang Hanghang , Sato Takahiro , Malouf Gabriel G. , Issa Jean-Pierre J.
Published: April 2023

Supplementary Fig. S1: Percentage of drugs per drug class among drug libraries used in the HTS; Supplementary Fig. S2: Synergistic GFP reactivation in YB5 cells by HDACi TSA and positive hits identified in the HTS; Supplementary Fig. S3: Optimization of the treatment schedule of the decitabine and proscillaridin A combination; Supplementary Fig. S4: Transcriptome analysis using Metascape; Supplementary Table S1: List of GO-Terms identified by Metascape analysis in gene data sets exclusively up-regulated by proscillaridin A treatment and exclusively up-regulated by the combination treatment; Supplementary Table S2: List of GO-Terms identified by Metascape analysis among down-regulated genes shared by proscillaridin A and the combinatorial treatment with decitabine; Supplementary Table S3: Antagonistic hits identified in combination HTS with sequential decitabine treatment; Supplementary Table S4. Antagonistic hits identified in combination HTS with simultaneous decitabine treatment; Supplementary Table S5. Antagonistic hits identified in combination HTS with sequential TSA treatment.
Supplementary Table S1 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

In silico analysis of HDAC4-targeting by miR-29b
Supplementary Figure S5 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

In vivo effects of miR-29b plus SAHA in KMS11 xenografts
Supplementary Figure S4 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

miR-29b inhibition impairs the effects of SAHA on NCI-H929 cell apoptosis and migration
Supplementary Figure S3 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

Analysis of apoptosis and autophagy triggered by SAHA and miR-29b mimics in MM cells
Supplementary Figure S2 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

miR-29b overexpression and HDAC4-silencing affect MM cell autophagy
Supplementary Table S1 and Supplementary Figures S1-S6 from CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Authors: Barker Holly E. , Patel Radhika , McLaughlin Martin , Schick Ulrike , Zaidi Shane , Nutting Christopher M. , Newbold Katie L. , Bhide Shreerang , Harrington Kevin J.
Published: April 2023

Supplementary Table S1 and 6 Supplementary Figures, S1-6. Table S1 - Patient samples from the PredictR-HNC study. Figure S1 - CCT244747 and paclitaxel IC50 determination and analysis of CCT244747 combination therapies. Figure S2 - Investigation of triple therapies using low concentrations of CCT244747 and paclitaxel. Figure S3 - Cell morphology 48 hours after treatment. HN5 cells exhibit an early increase in the S phase population. Figure S4 - High CHK1 and p-CHK1 cytoplasmic staining correlate with recurring HPV+ HNSCC tumours. Figure S5 - High CHK1, p-CHK1 and p-ATM expression correlate with recurring tumours. Figure S6 - The HPV+ recurring cell line SCC090 is radioresistant, exhibits strong CHK1 activation after exposure to radiation, and is highly sensitive to triple therapy.
Table S4 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Quantitative summary of the inhibition of RTK phosphorylation.
Supplementary from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

This file includes Supplemental materials and methods, Supplemental references, and Supplemental figure legends
Figure S5 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Combinations of multiple RTKis did not cause significant changes of the body weights.
Supplementary Tables 1-3 and Supplementary Figures 1-3 from Developing Antagonists for the Met-HGF/SF Protein–Protein Interaction Using a Fragment-Based Approach
Authors: Winter Anja , Sigurdardottir Anna G. , DiCara Danielle , Valenti Giovanni , Blundell Tom L. , Gherardi Ermanno
Published: April 2023

Additional information about the fragment screen, table summarising data for each compound, table showing docking results, figure showing controls for tumorsphere assay, cytotoxicity data, figure showing top three docking poses; Supplementary Table 1. Small molecule screening data; Supplementary Table 2: Binding affinity, competition for NK1 binding to MET928 and effect on HGF/SF-induced Akt and Erk1/2 phosphorylation in Vero cells of selected compounds related to MB1271 (structures 1-7), MB1297 (8-15) and MB621 (16-35); Supplementary Table 3: Docking results; Supplementary Figure 1: Control substances PHA665752 and Crizonitib showed reduction of mammosphere formation in tumorsphere assays; Supplementary Figure 2: Cytotoxicity assays show that most compounds (except compounds 16 and 23) do not show significant cytotoxicity beyond DMSO control; Supplementary Figure 3: Top-scoring docking poses of the three highest-ranking compounds in pockets One, Two and Three.
Supplementary Table S1. from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

The effects of PDT with Mal3-chlorin on ascites formation
Supplementary Figure S5 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

Involvement of GLUT1 in the uptake of Mal3-chlorin into pancreatic cancer cells.
Figure S1. In Vivo Effects Of Oxaliplatin And Niclosamide On Mouse Motor Excitability from Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response
Authors: Cerles Olivier , Benoit Evelyne , Chéreau Christiane , Chouzenoux Sandrine , Morin Florence , Guillaumot Marie-Anne , Coriat Romain , Kavian Niloufar , Loussier Thomas , Santulli Pietro , Marcellin Louis , Saidu Nathaniel E.B. , Weill Bernard , Batteux Frédéric , Nicco Carole
Published: April 2023

Excitability waveforms (means {plus minus} SD) were recorded at the plantar muscle in response to motor sciatic nerve stimulation of mice treated for 5 weeks with vehicle (black circles, n = 6), oxaliplatin (white circles, n = 7), oxaliplatin plus niclosamide (white squares, n = 9) or niclosamide alone (black squares, n = 7). (A) Strength-duration relationship. (B) Current-threshold relationship. (C) Threshold electrotonus in response to constant depolarizing (up) and hyperpolarizing (down) long-duration currents applied at sub-threshold intensity ({plus minus} 40%). (D) Recovery cycle. The oxaliplatin-induced effects are highlighted in grey with the corresponding parameter number beside. Note the absence of effect of oxaliplatin plus niclosamide and niclosamide alone on excitability waveforms, versus vehicle.
Supplementary Figure Legends from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

Supplementary Figure S1: Cell viability in pancreatic cancer cells treated by talaporfin with or without irradiation. Supplementary Figure S2: The luciferase luminescence intensities in AsPC1/luc cells treated by PDT with talaporfin or Mal3-chlorin. Cells were treated with talaporfin (1-16 Î¼M) or Mal3-chlorin (0.1-2 Î¼M) at 37{degree sign}C for 4 h, and then irradiated. After incubation for 24 h, cells were incubated for a short time at 37{degree sign}C with D-luciferin (150â€‰Î¼g/mL, Wako, Ltd.) in media. Luminescence was measured using a Lu mat LB 9507 instrument (EG&G BERTHOLD) and the data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 4 in each. Supplementary Figure S3: Average body weight transitions of mice during the experiment. Values are means {plus minus} SD, n = 7 in each. Supplementary Figure S4: Images of representative abdominal skin of mice from each group. Representative imaging of abdominal skin from mice at day 1, 8, and 15 on the treatment regimen as shown in Figure 4A: Control mice (left panel), talaporfin-mediated PDT mice (middle panel), and Mal3-chlorin-mediated PDT mice (right panel). Supplementary Figure S5: Involvement of GLUT1 in the uptake of Mal3-chlorin into pancreatic cancer cells. AsPC1/luc or BxPC3/luc cells were seeded into 96-well culture plates at a concentration of 5 Ã- 103 cells/well and incubated overnight. Cells were subsequently treated with WZB117 (0.1-30 Î¼M; EMD Chemicals, San Diego, CA, USA), which is a pharmacological GLUT1 inhibitor. After incubation for 24 h, cells were incubated for 4 h with Mal3-chlorin (1 Î¼M) and WZB117 (0.1-30 Î¼M), and levels of specific fluorescence were measured by Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). The data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 6 in each. Supplementary Figure S6: Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells. AsPC1/luc cells were seeded into 96-well culture plates at a concentration of 1 Ã- 103 - 8 Ã- 103 cells/well and incubated overnight. Cells were subsequently incubated for 4 h with Mal3-chlorin (0.05-2 Î¼M) and then fluorescence levels were measured using a Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). Values are means {plus minus} SD, n = 6 in each.
Supplementary Figure 6 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

Acute treatment with MN58b: effect on ABCB gene expression
Supplementary Table 1 from Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Authors: Kobayashi Yoshihisa , Azuma Koichi , Nagai Hiroki , Kim Young Hak , Togashi Yosuke , Sesumi Yuichi , Chiba Masato , Shimoji Masaki , Sato Katsuaki , Tomizawa Kenji , Takemoto Toshiki , Nishio Kazuto , Mitsudomi Tetsuya
Published: April 2023

IC50 values of Ba/F3 cells expressing EGFR Del18 or L858R with various types of resistant mutations.
Supplementary Figure 4 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

Detailed results of combination treatments
Captions from Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
Authors: Gimenez-Xavier Pol , Pros Eva , Bonastre Ester , Moran Sebastian , Aza Ana , Graña Osvaldo , Gomez-Lopez Gonzalo , Derdak Sophia , Dabad Marc , Esteve-Codina Anna , Hernandez Mora Jose R. , Salinas-Chaparro Diana , Esteller Manel , Pisano David , Sanchez-Cespedes Montse
Published: April 2023

Captions for supplementary Figures and Tables
Supplemental Figure 5 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Flow cytometric analysis of bone marrow from IMS-M2 tumor-bearing mice after 21 days of treatment with vehicle or entrectinib.
Supplemental Figure 2 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Entrectinib treatment inhibits ETV6-TRKC Y785 phosphorylation in a dose-dependent manner
Supplementary Table 1 from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Authors: Tu Xinyi , Kahila Mohamed M. , Zhou Qin , Yu Jia , Kalari Krishna R. , Wang Liewei , Harmsen William S. , Yuan Jian , Boughey Judy C. , Goetz Matthew P. , Sarkaria Jann N. , Lou Zhenkun , Mutter Robert W.
Published: April 2023

Supplementary Table 1 demonstrates single nucleotide variants, indels, copy number variants and copy number alterations in MCTNBC1
Supplementary Figure 3 from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Authors: Tu Xinyi , Kahila Mohamed M. , Zhou Qin , Yu Jia , Kalari Krishna R. , Wang Liewei , Harmsen William S. , Yuan Jian , Boughey Judy C. , Goetz Matthew P. , Sarkaria Jann N. , Lou Zhenkun , Mutter Robert W.
Published: April 2023

Supplementary Figure S3 demonstrates median animal weights for the comparison of Sham, VX-970, RT, or the combination.
Supplementary Figure 1 from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Authors: Tu Xinyi , Kahila Mohamed M. , Zhou Qin , Yu Jia , Kalari Krishna R. , Wang Liewei , Harmsen William S. , Yuan Jian , Boughey Judy C. , Goetz Matthew P. , Sarkaria Jann N. , Lou Zhenkun , Mutter Robert W.
Published: April 2023

Supplementary Figure S1 demonstrates that VX-970 exhibits minimal single agent activity at the dose which radiosensitized TNBC cells.
Supplementary Figures 1-2 from Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Authors: Namløs Heidi M. , Boye Kjetil , Mishkin Skyler J. , Barøy Tale , Lorenz Susanne , Bjerkehagen Bodil , Stratford Eva W. , Munthe Else , Kudlow Brian A. , Myklebost Ola , Meza-Zepeda Leonardo A.
Published: April 2023

Supplementary Figure 1. Radiological evaluation of response to treatment. Supplementary Figure 2. Histological grouping of FFPE sections according to normal tissue.
Supplementary figures 1-3 from XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB
Authors: Ming Mei , Wu Wenjun , Xie Bingqing , Sukhanova Madina , Wang Weige , Kadri Sabah , Sharma Shruti , Lee Jimmy , Shacham Sharon , Landesman Yosef , Maltsev Natalia , Lu Pin , Wang Y. Lynn
Published: April 2023

Suppl. Fig.1. Selinexor changes cell cycle progression in both ibrutinib-sensitive and -resistant MCL cells. Suppl. Fig.2. Selinexor retains IκBα and NF-κB subunits P65/P50 in the nuclei of Granta-519 cells. Suppl. Fig. 3. Selinexor retains IκBα and NF-κB subunits P65 in the nuclei.
Supplemental Figure 5 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Fig. 5. Sensitivity to Paclitaxel in AKT1-WT, AKT1-E17K xenographic tumors. Mice with subcutaneous (A) AKT1-WT or (B) AKT-E17K tumors were treated with paclitaxel. The ratio of treated and non-treated is shown in C.
Supplemental Figure 2 from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Supp. Fig. 2. AKT1-WT versus AKT1-E17K: Functional assays in vitro (Part 1). Proliferation assays performed three days after induction of AKT1-WT or AKT1-E17K protein under normal fetal bovine serum (10%), low serum (1%), hypoxia (4% O2), and with paclitaxel chemotherapy (0.5 μM). Error bars indicate mean {plus minus} SEM.
Table S3 from Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy
Authors: Chen Hui , Luthra Rajyalakshmi , Routbort Mark J. , Patel Keyur P. , Cabanillas Maria E. , Broaddus Russell R. , Williams Michelle D.
Published: April 2023

Thyroid carcinomas with mutations involving PI3K/AKT pathway
Table S2 from TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Authors: Hasako Shinichi , Terasaka Miki , Abe Naomi , Uno Takao , Ohsawa Hirokazu , Hashimoto Akihiro , Fujita Ryoto , Tanaka Kenji , Okayama Takashige , Wadhwa Renu , Miyadera Kazutaka , Aoyagi Yoshimi , Yonekura Kazuhiko , Matsuo Kenichi
Published: April 2023

Inhibitory activity and kinase selectivity of TAS6417 in biochemical assays
Supplementary Video 6 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 6 shows a confocal time-lapse series, showing MDCK cells treated with 80 ug of K16ApoE, immediately after labeling with Calcein-AM (green), which indicates live cells, and Ethidium homodimer-1 (red), indicating dead cells.
Supplementary Video 4 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 4 shows a confocal time-lapse series, showing MDCK cells treated with 20 ug of K16ApoE, immediately after labeling with Calcein-AM (green), which indicates live cells, and Ethidium homodimer-1 (red), indicating dead cells.
Supplementary Video 3 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 3 shows a confocal time-lapse series, showing a control sample of MDCK cells labeled with Calcein-AM (green), which indicates live cells, and Ethidium homodimer-1 (red), indicating dead cells.
Supplementary Video 2 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 2 shows sonographic visualization of the axial position of the heart of a NOD/SCID mouse injected with 1000 ug K16ApoE intravenously.
Supplementary Video 1 from Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood–Brain Barrier
Authors: Aasen Synnøve Nymark , Espedal Heidi , Holte Christopher Florian , Keunen Olivier , Karlsen Tine Veronika , Tenstad Olav , Maherally Zaynah , Miletic Hrvoje , Hoang Tuyen , Eikeland Anne Vaag , Baghirov Habib , Olberg Dag Erlend , Pilkington Geoffrey John , Sarkar Gobinda , Jenkins Robert B. , Sundstrøm Terje , Bjerkvig Rolf , Thorsen Frits
Published: April 2023

Supplementary Video 1 shows sonographic visualization of the axial position of the heart of a NOD/SCID mouse injected with 9 mg/mL NaCl intravenously.
Supplementary Video S1 from Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer
Authors: Aboubakar Nana Frank , Lecocq Marylène , Ladjemi Maha Zohra , Detry Bruno , Dupasquier Sébastien , Feron Olivier , Massion Pierre P. , Sibille Yves , Pilette Charles , Ocak Sebahat
Published: April 2023

Supplementary Video S1: PF-228's effect on NCI-446 SCLC cell line migration. NCI-H446 cell lines were grown to confluence in 12-well plates. Cell monolayers were wounded using a micropipette tip and floating cells were washed off with PBS. After overnight incubation, PF-228 at a concentration of 3µM or DMSO was added to culture medium. Cell movements within wounded area were monitored for 12h starting from the time drug was added using a Zeiss Axiovert 200M microscope (Zeiss, Thornwood, NY) at x200 magnification. Images were captured every 15-minutes from five different fields randomly selected in each well. They show that PF-228 decreased migration velocity in NCI-H446 cell lines.
Supplementary Table 3 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

The sequence of small interfering RNA
Supplemental Table 2 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

Individual drug characteristics and doses, maximum plasma levels and protein binding of panobinostat and belinostat in the two phase 1 studies
Supplementary Figure 4 from CCL26 Participates in the PRL-3–Induced Promotion of Colorectal Cancer Invasion by Stimulating Tumor-Associated Macrophage Infiltration
Authors: Lan Qiusheng , Lai Wei , Zeng Yujie , Liu Lu , Li Shoufeng , Jin Shaowen , Zhang Yang , Luo Xingxi , Xu Heyang , Lin Xiangan , Chu Zhonghua
Published: April 2023

Tumor volume and weight of CRC cells xenografts
Supplemental Figure 1 from Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma
Authors: Gupta Sumati , Albertson Daniel J. , Parnell Timothy J. , Butterfield Andrew , Weston Alexis , Pappas Lisa M. , Dalley Brian , O’Shea John M. , Lowrance William T. , Cairns Bradley R. , Schiffman Joshua D. , Sharma Sunil
Published: April 2023

Study Schema
Supplemental Figure S6 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

Minimum effective dose of eribulin in NCI-H2110 tumor-bearing mice.
Video 2 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Authors: Karlin Jeremy , Allen Jasmine , Ahmad Syed F. , Hughes Gareth , Sheridan Victoria , Odedra Rajesh , Farrington Paul , Cadogan Elaine B. , Riches Lucy C. , Garcia-Trinidad Antonio , Thomason Andrew G. , Patel Bhavika , Vincent Jennifer , Lau Alan , Pike Kurt G. , Hunt Thomas A. , Sule Amrita , Valerie Nicholas C.K. , Biddlestone-Thorpe Laura , Kahn Jenna , Beckta Jason M. , Mukhopadhyay Nitai , Barlaam Bernard , Degorce Sebastien L. , Kettle Jason , Colclough Nicola , Wilson Joanne , Smith Aaron , Barrett Ian P. , Zheng Li , Zhang Tianwei , Wang Yingchun , Chen Kan , Pass Martin , Durant Stephen T. , Valerie Kristoffer
Published: April 2023

U87/Centrin2-EGFP/H2B-mCherry/puro cells were seeded on dishes with cover slip bottoms, treated with AZ32 (3 uM), and irradiated (5 Gy). Time-lapse videos were recorded intermittently (every 7 min) over 16 hrs. Treatment results in 11% aberrant mitoses (see Fig. 3F).
Video 1 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Authors: Karlin Jeremy , Allen Jasmine , Ahmad Syed F. , Hughes Gareth , Sheridan Victoria , Odedra Rajesh , Farrington Paul , Cadogan Elaine B. , Riches Lucy C. , Garcia-Trinidad Antonio , Thomason Andrew G. , Patel Bhavika , Vincent Jennifer , Lau Alan , Pike Kurt G. , Hunt Thomas A. , Sule Amrita , Valerie Nicholas C.K. , Biddlestone-Thorpe Laura , Kahn Jenna , Beckta Jason M. , Mukhopadhyay Nitai , Barlaam Bernard , Degorce Sebastien L. , Kettle Jason , Colclough Nicola , Wilson Joanne , Smith Aaron , Barrett Ian P. , Zheng Li , Zhang Tianwei , Wang Yingchun , Chen Kan , Pass Martin , Durant Stephen T. , Valerie Kristoffer
Published: April 2023

U87/Centrin2-EGFP/H2B-mCherry/puro cells were seeded on dishes with cover slip bottoms and irradiated (5 Gy). Time-lapse videos were recorded intermittently (every 7 min) over 16 hrs. Treatment results in 2.7% aberrant mitoses (see Fig. 3F).
Supplemental Figure S1 from MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Authors: Cheng Xin , Li Jing , Tanaka Keigo , Majumder Utpal , Milinichik Andrew Z. , Verdi Arielle C. , Maddage Christopher J. , Rybinski Katherine A. , Fernando Shawn , Fernando Danielle , Kuc Megan , Furuuchi Keiji , Fang Frank , Uenaka Toshimitsu , Grasso Luigi , Albone Earl F.
Published: April 2023

Eribulin compound structures and synthetic methods
Supplementary Figure S7 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S7. Effect of RI phosphorylation on its oxidative stability. A and B, Images showing the proximity of a phosphoryl group on Thr81 or Ser382 to cysteine residues of RI. A phosphoryl group was installed computationally on OÎ³ of Thr81 and Ser382. RI is depicted as a gray ribbon; ANG is depicted as a green ribbon. The image was made with PDB entry 1z7x and the program PyMOL. C, Heat map of the change in Coulombic interaction energy between each cysteine thiolate on RI and the rest of the protein upon phosphorylation at Thr81, Ser177, Ser289, Ser382, or Ser405. In general, phosphorylation hinders thiolate formation at cysteine residues, especially those proximal to the phosphorylation site.
Supplementary Figure S5 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S5. Proximity of a phosphoryl group on Ser405 of RI to the phosphoryl group-binding subsites in an RIÂ·ptRNase complex. The image shows the superposition of the RNase AÂ·d(ATAAG) complex (PDB entry 1rcn) on the RNase 1Â·RI complex (PDB entry 1z7x). RI is depicted as a gray ribbon; RNase 1 is depicted as lines with its three active-site residues (His12, Lys41, and His119) depicted as sticks. Only the phosphoryl groups from PDB entry 1rcn are shown. A phosphoryl group was installed computationally on OÎ³ of Ser405; for clarity, only its phosphorus atom is shown. Phosphorus atoms are shown as orange spheres. Dashed lines depict phosphorus-phosphorus distances, which are 8.5-11.5 Ã…. The image was made with the program PyMOL from SchrÃ¶dinger (New York, NY).
Table S1 from Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin
Authors: Zhang Yong , Dong Yinhui , Melkus Michael W. , Yin Shutao , Tang Su-Ni , Jiang Peixin , Pramanik Kartick , Wu Wei , Kim Sangyub , Ye Min , Hu Hongbo , Lu Junxuan , Jiang Cheng
Published: April 2023

Table S1 shows upregulated genes by 10 nM bufalin over vehicle control by over 50% or more in LNCaP cells exposed for 24 h. Expressed as fold over vehicle control set as unity.
Supplementary Figure S3 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S3. MS/MS mass spectra of tryptic peptides from RI used to identify phosphorylation sites. Biotinylated RI was produced in HEK293T cells and purified with RNase A-affinity chromatography. Purified RI was digested with trypsin, and the ensuing peptides were analyzed to identify phosphorylation sites. Five sites were identified: Thr81, Ser177, Ser289, Ser382, and Ser405.
Figures S1-S5 from Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin
Authors: Zhang Yong , Dong Yinhui , Melkus Michael W. , Yin Shutao , Tang Su-Ni , Jiang Peixin , Pramanik Kartick , Wu Wei , Kim Sangyub , Ye Min , Hu Hongbo , Lu Junxuan , Jiang Cheng
Published: April 2023

Figure S1 shows A. Concentration-dependent reduction of number of adherent LNCaP cells exposed to increasing concentrations of bufalin for 96 h; B. Representative photomicrograph of LNCaP cells exposed to bufalin at 2 concentrations for 48 h. Figure S2 shows A, Western blot detection of c-PARP, AR, PSA in LNCaP cells exposed to bufalin for 48 h. B, Western blot detection of c-PARP, AR, PSA in LNCaP cells exposed to bufalin for 24 h. Figure S3 shows gross appearance of paraffin embedded tumors (3rd-8th ranked for each group) selected for biomarker analyses. Figure S4 shows Western blot detection of HK2 (hexokinase-2), p-AKT and AKT in tumors from vehicle- or bufalin-treated mice. PC3 cell extract and LNCaP extract (LN) were used as positive control for HK2 and active AKT (p-AKT), respectively. Figure S5 shows a schematic integration of bufalin induced cellular effects to inhibit LNCaP prostate tumor growth.
Supplementary Figure S1 from A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells
Authors: Hoang Trish T. , Tanrikulu I. Caglar , Vatland Quinn A. , Hoang Trieu M. , Raines Ronald T.
Published: April 2023

Supplementary Figure S1. Effect of kinase inhibitors and QBI-139 on the viability of human melanoma cells. Cell viability was measured with a tetrazolium dye-based assay for metabolic activity. EC50 values are listed in the table.
Supplementary Tables S1-S4 from Treating Tissue Factor–Positive Cancers with Antibody–Drug Conjugates That Do Not Affect Blood Clotting
Authors: Theunissen Jan-Willem , Cai Allen G. , Bhatti Maryam M. , Cooper Anthony B. , Avery Andrew D. , Dorfman Ryan , Guelman Sebastian , Levashova Zoia , Migone Thi-Sau
Published: April 2023

Supplementary Table S1. Screening Data; Supplementary Table S2. Binding Data; Supplementary Table S3. TGA Data; Supplementary Table S4. ADC Data With Ranking
Supplementary Table S1 from JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers
Authors: Pitroda Sean P. , Stack Melinda E. , Liu Gene-Fu , Song Sui-Sui , Chen Lucy , Liang Hua , Parekh Akash D. , Huang Xiaona , Roach Paul , Posner Mitchell C. , Weichselbaum Ralph R. , Khodarev Nikolai N.
Published: April 2023

Supplementary Table 1. Clonogenic survival of NSCLC cell lines after cytotoxic therapy.
Supplementary Figures 1-9 from JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non–small Cell Lung Cancers
Authors: Pitroda Sean P. , Stack Melinda E. , Liu Gene-Fu , Song Sui-Sui , Chen Lucy , Liang Hua , Parekh Akash D. , Huang Xiaona , Roach Paul , Posner Mitchell C. , Weichselbaum Ralph R. , Khodarev Nikolai N.
Published: April 2023

Supplemental Figure S1. Comparison of clonogenic survival fractions of various cancer cell lines after treatment with SAR302503 and Ruxolitinib. Supplemental Figure S2. KRAS mutation by treatment sensitivities in NSCLC cell lines. Supplementary Figure S3. The response of NCIH1944 xenografts to ionizing radiation. Supplemental Figure S4. Top-ranked pathways in SAR sensitive NSCLC cell lines. Supplemental Figure S5. Cancer growth and proliferation gene network in SAR-sensitive NSCLC. Supplemental Figure S6. ROC analysis of SAR sensitivity by TSP-IRDS scores. Supplemental Figure S7. Distribution of TSP-IRDS scores in clinical NSCLCs. Supplemental Figure S8. TSP-IRDS predicts survival in clinical NSCLC. Supplemental Figure S9. TSP-IRDS scores predict the benefit of adjuvant cisplatin-based chemotherapy in clinical NSCLC. Supplementary Figure and Table Legends
Figure S7 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of RIPK inhibition on monomeric MLKL expression.
Figure S6 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of necrosulfamide on cell viability and MLKL oligomerization.
Figure S2 from Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer
Authors: Zhang Xuewei , Kitatani Kazuyuki , Toyoshima Masafumi , Ishibashi Masumi , Usui Toshinori , Minato Junko , Egiz Mahy , Shigeta Shogo , Fox Todd , Deering Tye , Kester Mark , Yaegashi Nobuo
Published: April 2023

Effects of ceramide nanoliposomes on cell death in multiple ovarian cancer cell lines.
Supplemental Figure S4 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Authors: Dong Jun , Wu Zeyu , Wang Dan , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplemental Figure S4 shows the effect of 18BBQU on AR protein level in C4-2 cells.
Supplemental Figure S3 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Authors: Dong Jun , Wu Zeyu , Wang Dan , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplemental Figure S3 shows the effect of Hsp70 knockdown on AR protein level in LNCaP cells.
Supplementary Figure from Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition
Authors: Jin Mei Hua , Nam Ah-Rong , Park Ji Eun , Bang Ju-Hee , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

S1- basal expression level S2- MTT Assay and Colony Forming Assay S3- Combination data S4- Trastuzumab monotherapy in vivo
Supplemental Figure S1 from Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells
Authors: Dong Jun , Wu Zeyu , Wang Dan , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplemental Figure S1 shows the Hsp70 and Hsc70 peptide sequences identified by proteomics.
Fig. S7 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S7. Effects of mimic-miR-29b-1-3p and MIRTX on cell proliferation. MIRTX exhibited a stronger inhibition of cell proliferation in DLD1 than mimic-miR-29b-3p.
Fig. S5 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S5. Evaluation of the toxicity of super carbonate apatite-MIRTX conjugate and effect of systemic administration of formulated MIRTX on tumor growth in vivo. The DLD1 xenograft mouse models received intravenous administrations of MIRTX or control-miR using super carbonate apatite (sCA) as a vehicle on days 0, 2, 4, 7, 9, 12, 14, and 16 via a tail vein injection. Each injection contained 40 μg of formulated oligo with a 40% conjugation rate. Tumors were resected on day 18. (A) Blood chemistry tests were performed on day 18 for the parent, treated with sCA-control-miR, and treated with sCA-MIRTX. NS: not significant. (B) Hematoxylin and eosin-stained section of each organ tissue (brain, heart, lung, liver, spleen, kidney, colon) revealed no particular histological damage in formulated sCA-MIRTX-treated mice. (C) Tumor weights were evaluated for the parent (n = 8), treated with sCA-control-miR (n = 8), and treated with sCA-MIRTX (n = 8). Injection of sCA-MIRTX significantly decreased tumor weights. (D) Another cohort using HT29. All data represent mean {plus minus} SD. *p < 0.01.
Fig. S4 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells
Authors: Inoue Akira , Mizushima Tsunekazu , Wu Xin , Okuzaki Daisuke , Kambara Nanami , Ishikawa Sho , Wang Jiaqi , Qian Yamin , Hirose Haruka , Yokoyama Yuhki , Ikeshima Ryo , Hiraki Masayuki , Miyoshi Norikatsu , Takahashi Hidekazu , Haraguchi Naotsugu , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S4. Effects of MIRTX on KRAS downstream signaling activity. All cells were seeded onto 96-well plates and transfected with SRE luciferase reporter vector (pGL4.33[luc2P/SRE/Hygro]; Promega) or with AP1 luciferase reporter vector (pGL4.44[luc2P/AP1-RE/Hygro]; Promega). Renilla luciferase reporter vector (pRL-CMV, Promega) was co-transfected to evaluate the transfection efficiency. Forty-eight hours after co-transfection with both reporter vectors and the target miRNA, cells were collected and luminescence was measured with the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. SRE and AP1 transcriptional luciferase activities in DLD1, SW480, and HT29 cells treated with miR-NC or MIRTX. Data showed that MIRTX did not suppress SRE or AP1 transcriptional activities in these cell lines. All data represent mean {plus minus} SD.
Supplementary Table S1 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition
Authors: Ma Shaolin , Pradeep Sunila , Villar-Prados Alejandro , Wen Yunfei , Bayraktar Emine , Mangala Lingegowda S. , Kim Mark Seungwook , Wu Sherry Y. , Hu Wei , Rodriguez-Aguayo Cristian , Leuschner Carola , Liang Xiaoyan , Ram Prahlad T. , Schlacher Katharina , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Table S1. The IC50s of EP-100 against ovarian cancer cells after 4-, 24-, and 72-h treatment.